Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan (Clinical and Experimental Nephrology, (2019), 23, 2, (231-243), 10.1007/s10157-018-1632-9)

Tetsuhiro Tanaka; Masaomi Nangaku; Enyu Imai; Yoshiharu Tsubakihara; Masatoshi Kamai; Michihito Wada; Shinji Asada; Tadao Akizawa

doi:10.1007/s10157-019-01694-w

Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan (Clinical and Experimental Nephrology, (2019), 23, 2, (231-243), 10.1007/s10157-018-1632-9)

Tetsuhiro Tanaka, Masaomi Nangaku, Enyu Imai, Yoshiharu Tsubakihara, Masatoshi Kamai, Michihito Wada, Shinji Asada, Tadao Akizawa

MED - Medical Sciences

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the original publication of the article, two sentences in the “Results” section were published incorrectly.

Original language	English
Pages (from-to)	435
Number of pages	1
Journal	Clinical and experimental nephrology
Volume	23
Issue number	3
DOIs	https://doi.org/10.1007/s10157-019-01694-w
Publication status	Published - 2019 Mar 15

ASJC Scopus subject areas

Physiology
Nephrology
Physiology (medical)

Access to Document

10.1007/s10157-019-01694-w

Fingerprint

Dive into the research topics of 'Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan (Clinical and Experimental Nephrology, (2019), 23, 2, (231-243), 10.1007/s10157-018-1632-9)'. Together they form a unique fingerprint.

Cite this

Tanaka, T., Nangaku, M., Imai, E., Tsubakihara, Y., Kamai, M., Wada, M., Asada, S., & Akizawa, T. (2019). Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan (Clinical and Experimental Nephrology, (2019), 23, 2, (231-243), 10.1007/s10157-018-1632-9). Clinical and experimental nephrology, 23(3), 435. https://doi.org/10.1007/s10157-019-01694-w

Correction to : Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan (Clinical and Experimental Nephrology, (2019), 23, 2, (231-243), 10.1007/s10157-018-1632-9). / Tanaka, Tetsuhiro; Nangaku, Masaomi; Imai, Enyu et al.

In: Clinical and experimental nephrology, Vol. 23, No. 3, 15.03.2019, p. 435.

Research output: Contribution to journal › Comment/debate › peer-review

Tanaka, T, Nangaku, M, Imai, E, Tsubakihara, Y, Kamai, M, Wada, M, Asada, S & Akizawa, T 2019, 'Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan (Clinical and Experimental Nephrology, (2019), 23, 2, (231-243), 10.1007/s10157-018-1632-9)', Clinical and experimental nephrology, vol. 23, no. 3, pp. 435. https://doi.org/10.1007/s10157-019-01694-w

Tanaka T, Nangaku M, Imai E, Tsubakihara Y, Kamai M, Wada M et al. Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan (Clinical and Experimental Nephrology, (2019), 23, 2, (231-243), 10.1007/s10157-018-1632-9). Clinical and experimental nephrology. 2019 Mar 15;23(3):435. doi: 10.1007/s10157-019-01694-w

Tanaka, Tetsuhiro ; Nangaku, Masaomi ; Imai, Enyu et al. / Correction to : Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan (Clinical and Experimental Nephrology, (2019), 23, 2, (231-243), 10.1007/s10157-018-1632-9). In: Clinical and experimental nephrology. 2019 ; Vol. 23, No. 3. pp. 435.

@article{33d8fbea25cc4ca9a23d94ee7df7015c,

title = "Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan (Clinical and Experimental Nephrology, (2019), 23, 2, (231-243), 10.1007/s10157-018-1632-9)",

abstract = "In the original publication of the article, two sentences in the “Results” section were published incorrectly.",

author = "Tetsuhiro Tanaka and Masaomi Nangaku and Enyu Imai and Yoshiharu Tsubakihara and Masatoshi Kamai and Michihito Wada and Shinji Asada and Tadao Akizawa",

note = "Publisher Copyright: {\textcopyright} 2019, Japanese Society of Nephrology.",

year = "2019",

month = mar,

day = "15",

doi = "10.1007/s10157-019-01694-w",

language = "English",

volume = "23",

pages = "435",

journal = "Clinical and Experimental Nephrology",

issn = "1342-1751",

publisher = "Springer Japan",

number = "3",

}

TY - JOUR

T1 - Correction to

T2 - Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan (Clinical and Experimental Nephrology, (2019), 23, 2, (231-243), 10.1007/s10157-018-1632-9)

AU - Tanaka, Tetsuhiro

AU - Nangaku, Masaomi

AU - Imai, Enyu

AU - Tsubakihara, Yoshiharu

AU - Kamai, Masatoshi

AU - Wada, Michihito

AU - Asada, Shinji

AU - Akizawa, Tadao

PY - 2019/3/15

Y1 - 2019/3/15

N2 - In the original publication of the article, two sentences in the “Results” section were published incorrectly.

AB - In the original publication of the article, two sentences in the “Results” section were published incorrectly.

UR - http://www.scopus.com/inward/record.url?scp=85060661390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060661390&partnerID=8YFLogxK

U2 - 10.1007/s10157-019-01694-w

DO - 10.1007/s10157-019-01694-w

M3 - Comment/debate

C2 - 30673934

AN - SCOPUS:85060661390

SN - 1342-1751

VL - 23

SP - 435

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

IS - 3

ER -

Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan (Clinical and Experimental Nephrology, (2019), 23, 2, (231-243), 10.1007/s10157-018-1632-9)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this